Navarro-Ruíz, EvaPeña, M ÁngelesDahma, ZaidÁlvarez Álvarez, CovadongaTorrado Salmerón, Carlos FélixTorre Iglesias, Paloma Marina De La2024-01-102024-01-102022-07-20NAVARRO-RUÍZ, Eva, et al. Multiparticulate systems of meloxicam for colonic administration in cancer or autoimmune diseases. Pharmaceutics, 2022, vol. 14, no 7, p. 1504.1999-492310.3390/pharmaceutics14071504https://hdl.handle.net/20.500.14352/92180The aim of this research is the development of new colonic release systems of meloxicam (MLX) a non-steroidal anti-inflammatory drug (NSAIDs) with pH and time-dependent vehicles for cancer or autoimmune diseases. The colon has a higher pH than the rest of the gastrointestinal tract (GIT) and this can be used as a modified release strategy. Eudragit® polymers are the most widely used synthetic products in the design of colonic release formulations because they might offer mucoadhesiveness and pH-dependent release. Colonic delivery systems produced with pH-dependent and permeable polymers (FS-30D) or with pH-independent and low permeability polymers (NM-30D), must dissolve at a pH range of 6.0–7.0 to delay the release of the drug and prevent degradation in the GIT, before reaching the colon. The conditions prepared to simulate a gastrointestinal transit showed the CNM multiparticulate system, composed of Eudragit® NM and cellulose, as the best release option for MLX with a more sustained release with respect to the other formulations. CNM formulation followed Higuchi and First-order release kinetics, thus MLX release was controlled by a combination of diffusion and polymers swelling/eroding processes.engAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/journal articlehttps://www.mdpi.com/journal/pharmaceuticsopen access615.4663/665Multiparticulate systemAutoimmune diseaseCancerColonic administrationMeloxicamCiencias BiomédicasTecnología de los alimentos32 Ciencias Médicas24 Ciencias de la Vida33 Ciencias Tecnológicas